Opko Health has entered into a definitive agreement to acquire Prost-Data, trading as OURLab, a Nashville, TN-based CLIA laboratory with 18 phlebotomy sites throughout the US and a nationwide salesforce calling primarily on urologists.
OURLab provides Opko with a commercial platform to support the near-term US commercial launch of its panel of kallikrein biomarkers and associated algorithm (4Kscore), for the detection of prostate cancer. Opko 4Kscore is the result of a decade of research by scientists in Europe and the US and has been demonstrated in more than 10,000 patients to predict the probability of positive biopsies in men suspected of having prostate cancer.
Studies have shown that the use of 4Kscore may reduce the number of unnecessary prostate biopsies by 50 per cent or more, avoiding the frequent complications of pain, bleeding and infection, which sometimes require hospitalisation. The data indicated that even with the significant reduction in the number of biopsies performed, the probability of delaying diagnosis of a high grade cancer was only 0.6 per cent. Men whose 4Kscore is low enough to not lead to biopsies would be followed with active surveillance by the urologist.
Upon completion of the OURLab acquisition, Dr Jonathan Oppenheimer, OURLab's founder and CEO, will assume the role of CEO of Opko's Diagnostics division.